25 April 2025
25 April 2025
Following in the footsteps of several pharma companies, life sciences giant Thermo Fisher is doubling down on investments at its US sites.
Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.
MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.
Pharma executives emphasise that without urgent action, Europe may face a decline and an acceleration in the departure of companies.
The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar strategic collaborations.
The company anticipates submitting a biologics licence application for accelerated approval in the US in early 2026.
The financial injection comprises a $30m Series A round and a $70m Series B round.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
